Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
Johnson and Johnson
Boehringer Ingelheim
McKesson

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,138,229

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,138,229
Title:Compositions and methods of delivery of pharmacological agents
Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), Trieu; Vuong (Calabasas, CA)
Assignee: Abraxis Bioscience, LLC (Los Angeles, CA)
Application Number:12/910,693
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,138,229
Patent Claim Types:
see list of patent claims
Composition; Use;

Recent additions to Drugs Protected by US Patent 8,138,229

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION 021660 Jan 7, 2005 RX Yes   Start Trial Y   Start Trial U-1092 TREATMENT OF BREAST CANCER
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION 021660 Jan 7, 2005 RX Yes   Start Trial Y   Start Trial U-1290 TREATMENT OF LUNG CANCER
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION 021660 Jan 7, 2005 RX Yes   Start Trial Y   Start Trial U-1434 TREATMENT OF PANCREATIC CANCER
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,138,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF PANCREATIC CANCER   Start Trial
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF BREAST CANCER   Start Trial
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF LUNG CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,138,229

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003299590   Start Trial
Brazil 0317134   Start Trial
Canada 2509365   Start Trial
China 102343094   Start Trial
China 103405405   Start Trial
China 104587479   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Medtronic
Merck
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.